Yes, Venofer (IV iron sucrose) is appropriate and safe for a 28-week pregnant woman with hemoglobin 8.3 g/dL
Intravenous iron sucrose should be administered to this patient, as published studies have demonstrated safety and efficacy after the first trimester without adverse maternal or fetal outcomes, and untreated iron deficiency anemia at this hemoglobin level poses significant risks including preterm delivery, low birth weight, and postpartum hemorrhage. 1
Clinical Rationale
Safety Profile in Second/Third Trimester
The FDA label for Venofer explicitly states that published randomized controlled trials and prospective observational studies on intravenous iron sucrose use after the first trimester have not reported adverse maternal or fetal outcomes 1. At 28 weeks gestation, this patient is well into the third trimester where safety data is robust.
Disease-Associated Risks Requiring Treatment
The FDA label emphasizes that iron deficiency anemia during pregnancy should be treated because untreated IDA is associated with 1:
- Postpartum anemia
- Increased risk for preterm delivery
- Low birth weight
With hemoglobin at 8.3 g/dL, this patient has moderate anemia requiring intervention to prevent these complications.
Dosing and Administration Considerations
Timing Matters for Efficacy
Recent high-quality evidence demonstrates that earlier administration yields better outcomes 2, 3:
- IVFe given at <34 weeks produces greater hemoglobin improvement (2.5 g/dL vs 1.3 g/dL) compared to ≥34 weeks 2
- Maximum benefit occurs with ≥6-8 weeks latency before delivery 2, 3
- At 28 weeks, this patient has optimal timing for treatment
Dose Requirements
Based on 2025 data, doses ≥800 mg with ≥6 weeks latency produce the strongest hemoglobin improvement (2.6-3.1 g/dL increase) 2. Multiple doses (at least 3) demonstrate statistically significant hemoglobin change compared to no treatment 3.
The total iron deficit should be calculated using Ganzoni's formula with an additional 500 mg depot allowance 4. Typical dosing is 300 mg iron diluted in 300 mL normal saline every third day until the calculated dose is administered 4.
Safety Monitoring
Important Caveats
While generally safe, be aware of 1:
- Severe hypersensitivity reactions (including circulatory failure, shock) can occur and may cause fetal bradycardia, especially in second/third trimester
- Monitor during infusion for signs of complement activation-related pseudo-allergy (CARPA): flushing, myalgias, back pain, chest pressure
- These reactions typically occur at infusion start and resolve without treatment
- Slow infusion rate if symptoms develop
Fetal Monitoring
Fetal monitoring during or following IV iron administration is not required and expert consensus recommends against it 5. The 2024 guidelines explicitly state this is unnecessary.
Expected Outcomes
Real-world effectiveness data shows 6, 4:
- Substantial hemoglobin improvement by 6 weeks post-treatment
- Mean increase of 3.2 g/dL at 6-month follow-up 4
- Favorable maternal delivery patterns and neonatal outcomes 6
- Only 2 of 295 patients required peripartum transfusion in one large series 2
Contraindications to Oral Iron
While not explicitly stated in your question, IV iron is particularly indicated when oral iron is inadequate, poorly tolerated, or when rapid correction is needed 6. At 28 weeks with Hgb 8.3 g/dL, oral iron alone is unlikely to achieve adequate correction before delivery.